Increasing Prevalence Of Heart Disease Drives Growth Of Cardiac Biomarkers Diagnostics Market, Says Frost & Sullivan
LONDON, Dec. 12, 2012 /PRNewswire/ -- Cardiovascular disease (CVD) is the main cause of death in the EU, killing over 2 million people annually and costing the economy nearly €192 billion. Prevention, through constant monitoring of heart health, is seen as the best way to tackle this high death rate.
The most accurate way of monitoring heart health is through cardiac marker testing. Regular monitoring of cardiac health through brain natriuretic peptide (BNP) testing is being practiced across Europe, thereby boosting the cardiac marker testing market.
New analysis from Frost & Sullivan ( http://www.healthcare.frost.com), Analysis of European Cardiac Biomarkers Diagnostics Market, finds that the market earned revenues of about $607.9 million in 2011 and estimates this to double to reach $1,216.0 million in 2018. The research covers acute myocardial infarction (AMI) and congestive heart failure (CHF) biomarkers diagnostics.
The increasing role of cardiac markers in patient triaging is further boosting market expansion. Effective implementation of cardiac markers can enable decreased bed occupancy, reduced hospital costs and physician time."Cardiac markers rank among the best available tools to assess the patient's status," notes Frost & Sullivan Senior Research Analyst K. Srinivas Sashidhar. "For instance, in cases where a test is positive for certain markers, especially cardiac troponin, this would indicate a heart attack. Subsequently, the appropriate treatments and interventions could be administered." Due to the urgent nature of myocardial infarction, commonly known as a heart attack, healthcare practitioners have to obtain rapid results for immediate diagnosis and treatment. This need for quick turnaround times has fuelled interest in point-of-care (POC) cardiac testing. As these trends accelerate market development, saturation will pose a key restraint, especially for the troponin testing segment.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV